AU2002312897A1 - Drugs for the treatment of the alzheimer disease - Google Patents
Drugs for the treatment of the alzheimer diseaseInfo
- Publication number
- AU2002312897A1 AU2002312897A1 AU2002312897A AU2002312897A AU2002312897A1 AU 2002312897 A1 AU2002312897 A1 AU 2002312897A1 AU 2002312897 A AU2002312897 A AU 2002312897A AU 2002312897 A AU2002312897 A AU 2002312897A AU 2002312897 A1 AU2002312897 A1 AU 2002312897A1
- Authority
- AU
- Australia
- Prior art keywords
- drugs
- treatment
- alzheimer disease
- alzheimer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000985A ITMI20010985A1 (en) | 2001-05-15 | 2001-05-15 | DRUGS FOR ALZHEIMER DISEASE |
| ITMI2001A000985 | 2001-05-15 | ||
| PCT/EP2002/005165 WO2002092072A2 (en) | 2001-05-15 | 2002-05-10 | Drugs for the treatment of the alzheimer disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002312897A1 true AU2002312897A1 (en) | 2002-11-25 |
Family
ID=11447649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002312897A Abandoned AU2002312897A1 (en) | 2001-05-15 | 2002-05-10 | Drugs for the treatment of the alzheimer disease |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002312897A1 (en) |
| IT (1) | ITMI20010985A1 (en) |
| WO (1) | WO2002092072A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10702571B2 (en) | 2015-12-03 | 2020-07-07 | The University Of North Carolina At Pembroke | Materials for cathepsin B enhancement and methods of use |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150368A0 (en) | 1999-12-23 | 2002-12-01 | Nitromed Inc | Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use |
| AU2003208525B9 (en) | 2002-02-04 | 2009-08-27 | Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda | Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
| CA2487414A1 (en) | 2002-06-11 | 2003-12-18 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| JP2005539089A (en) | 2002-07-03 | 2005-12-22 | ニトロメッド インコーポレーティッド | Nitrosated non-steroidal anti-inflammatory compounds, compositions and methods of use |
| JP2005538110A (en) | 2002-07-29 | 2005-12-15 | ニトロメッド インコーポレーティッド | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| US20040138296A1 (en) * | 2002-08-12 | 2004-07-15 | Pharmacia Corporation | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease |
| ITMI20021861A1 (en) * | 2002-08-29 | 2004-02-29 | Nicox Sa | NITROXIALKYL ESTER SYNTHESIS PROCESS OF CARBOXYLIC ACIDS, INTERMEDIATES THAT CAN BE USED IN THAT PROCEDURE AND THEIR PREPARATION. |
| US7585997B2 (en) * | 2003-12-31 | 2009-09-08 | Chesterford Enterprises Limited | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| BRPI0515218A (en) | 2004-08-26 | 2008-07-08 | Nicholas Piramal India Ltd | compound, pharmaceutical composition, method for the treatment of a mammal or human, method of using the compound, new intermediates, use of the new intermediates, process for the preparation of a compound |
| GB0606015D0 (en) | 2006-03-28 | 2006-05-03 | Merck Sharp & Dohme | therapeutic agents |
| US20100168228A1 (en) * | 2006-10-13 | 2010-07-01 | Reliance Life Sciences Pvt. Ltd. | Novel chemotherapeutic agents against inflammation and cancer |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| CA2692805A1 (en) | 2007-07-09 | 2009-01-15 | Nicox S.A. | Use of nitric oxide releasing compounds in the treatment of chronic pain |
| CN101820755B (en) | 2007-08-10 | 2013-05-15 | 巴赛尔·雷盖斯 | Anti-inflammatory compounds and uses thereof |
| EP2378879A4 (en) | 2008-12-16 | 2012-06-06 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| PT2699242T (en) | 2011-04-19 | 2018-01-22 | Alfama Inc | Carbon monoxide releasing molecules and uses thereof |
| JP6134710B2 (en) | 2011-07-21 | 2017-05-24 | アルファーマ インコーポレイテッドAlfama,Inc. | Ruthenium monoxide releasing molecules and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
| IT1256345B (en) * | 1992-08-20 | 1995-12-01 | NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION | |
| IT1256450B (en) * | 1992-11-26 | 1995-12-05 | Soldato Piero Del | NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION |
| IT1311924B1 (en) * | 1999-04-13 | 2002-03-20 | Nicox Sa | PHARMACEUTICAL COMPOUNDS. |
-
2001
- 2001-05-15 IT IT2001MI000985A patent/ITMI20010985A1/en unknown
-
2002
- 2002-05-10 WO PCT/EP2002/005165 patent/WO2002092072A2/en not_active Ceased
- 2002-05-10 AU AU2002312897A patent/AU2002312897A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10702571B2 (en) | 2015-12-03 | 2020-07-07 | The University Of North Carolina At Pembroke | Materials for cathepsin B enhancement and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20010985A1 (en) | 2002-11-15 |
| WO2002092072A2 (en) | 2002-11-21 |
| ITMI20010985A0 (en) | 2001-05-15 |
| WO2002092072A3 (en) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| AU2003219690A1 (en) | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease | |
| HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL150742A0 (en) | Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease | |
| AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| AU2002334870B8 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| AU2002312897A1 (en) | Drugs for the treatment of the alzheimer disease | |
| AU2003217275A1 (en) | Azabicyclic compounds for the treatment of disease | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| AU2002210385A1 (en) | Furazanyl-triazole derivates for the treatment of diseases | |
| AU2002240359A1 (en) | Pharmaceutical composition for the treatment of alopecia | |
| AU2003251904A1 (en) | Combinations of drugs for the treatment of neoplasms | |
| AU2003303141A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| AU2002322263A1 (en) | Eglin c based drugs for treatment of disease | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| AUPR610501A0 (en) | Treatment of parasitic disease | |
| AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
| AU2002348105A1 (en) | Oral dosage forms for improving the bioavailability of therapeutic agents | |
| AU2002359282A1 (en) | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | |
| AU2002316622A1 (en) | Aminediols for the treatment of alzheimer's disease | |
| AU2002320537A1 (en) | Diaminediols for the treatment of alzheimer's disease | |
| AU2002309857A1 (en) | Vaccines for the treatment of autoimmune disease | |
| AU2002238991A1 (en) | Novel drugs for preventing/treating immunopathic diseases | |
| AU2002365654A1 (en) | Treatment of diseases via the skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |